Thanks Afford, but I do find the big $ side of things worrisome. I too think that demonstrated efficacy will take care of a lot of pot-holes or at least make them moot... but I don't know what to think of the big $ issues that Pyrrho points at.
One thing I noticed is that Pyrrho quotes R&D expenditures and divides by batches of DCVax-L to infer per batch cost. Nothing in there for automated mfg development. Such has been completed for Direct, and that had to cost a lot of money. If such is ongoing for L, which is much more difficult, that too has to be very expensive.... but expensive enough to account for the big $ in question? I'm not sure. It is a loooooot of money. Automated mfg is incredibly expensive... but is it that expensive? Not sure.
If not, maybe we get a chunk of Cognate when all is said and done? Nobody seems to think so. Best prognosis is just many shares of NWBO returned from Cognate. But as you say, that would be pretty good too.
News 
Market Data 
Discover 
AI
